

Application No. 09/277,401
Art Unit 1652

February 2, 2001

In the Description

Page 59, line 12, change "and" to --or--.

In the Claims

B1 Summary
DI
20. (Amended) A pharmaceutical composition for increasing the level of LIPG polypeptide in a patient comprising an LIPG polypeptide [and a pharmaceutically acceptable carrier].

Please cancel Claims 2 to 6, 9, 12, 17, 18, 26, 27, 33, 36, 38, 42, 48, 54, and 60 to 62 without prejudice.

Please add the following claims.

--66. A composition according to Claim 20 comprising also an enhancer for enhancing the enzymatic activity of LIPG polypeptide.

2
67. A composition according to Claim 20 comprising also an enhancer which enhances the enzymatic reaction between LIPG polypeptide and LDL cholesterol relative to the reaction between LIPG polypeptide and HDL cholesterol and apo AI.

68. A composition according to Claim 20 comprising also an enhancer which enhances the enzymatic reaction between LIPG

Application No. 09/277,401
Art Unit 1652

February 2, 2001

polypeptide and VLDL cholesterol relative to the reaction between LIPG polypeptide and HDL cholesterol and apo AI.

69. A composition according to Claim 20 wherein said LIPG polypeptide is a recombinant polypeptide.

70. A composition according to Claim 20 wherein said LIPG polypeptide is a synthetic polypeptide.

71. A composition according to Claim 20 wherein said LIPG polypeptide is a natural polypeptide.

72. A composition according to Claim 20 wherein said LIPG polypeptide is of human origin.

73. A composition according to Claim 20 wherein said LIPG polypeptide is of rabbit origin.

74. A composition according to Claim 20 wherein said LIPG polypeptide is that set forth in SEQ ID NO: 6 or a fragment or a variant of said SEQ ID NO: 6.

75. A composition according to Claim 20 wherein said LIPG polypeptide is that set forth in SEQ ID NO: 8 or a fragment or a variant of said SEQ ID NO: 8.

Application No. 09/277,401
Art Unit 1652

February 2, 2001

76. A composition according to Claim 20 wherein said LIPG polypeptide is that set forth in SEQ ID NO: 10 or a fragment or a variant of said SEQ ID NO: 10.

77. A composition according to Claim 20 comprising also a pharmaceutically acceptable carrier.

78. A composition according to Claim 20 in the form of a biologically-compatible solution.

79. A composition according to Claim 78 wherein said biologically-compatible solution is an aqueous buffer.

80. A composition according to Claim 78 wherein said biologically-compatible solution is selected from group consisting of: Tris; phosphate; and HEPES.

81. A composition according to Claim 78 wherein said biologically-compatible solution is an aqueous buffer including salt ions which are present in concentration which is similar to physiological levels.

82. A composition according to Claim 20 comprising also a stabilizer.